Seminomas account for about 30-40% of all testicular tumours. These are usually is found in men in their 30s and 40s. The condition is usually localised to the testes, although in about 25% of cases it has spread to lymph nodes. Non-seminomas account for 60% of all testicular tumours; subcategories of these tumours are listed below. Non-seminoma tumours often contain more than one of the following cell types: Testicular cancer is an abnormal, rapid, and invasive growth of cancerous (malignant) cells in the testicles. Embryonal carcinoma (about 20% of testicular cancers) occurs in 20-30 year olds and is highly malignant. It grows rapidly and spreads to the lung and liver. Yolk sac tumour (about 60% of all testicular cancers in young boys). Teratomata (about 7% of testicular cancers in adult men and 40% in young boys). Choriocarcinoma is rare. Stromal cell tumours are a kind of tumour that is made of Leydig cells (testosterone-secreting cells), Sertoli cells (cells where sperm matures), and granulose cells. These tumours account for only 3-4% of all testicular tumours. However, they do make up nearly 20% of all childhood testicular tumours. These tumours may secrete a hormone -- estradiol -- that can cause one of the symptoms of testicular cancer, gynecomastia (excessive development of breast tissue). This book presents leading-edge research in the field.
Testicular cancer (TC) is the most common cancer in males aged 20-40 years, with a worldwide incidence of 7.5 per 100,000, but the rates vary considerably between countries and ethnic groups and there is evidence also for an increasing incidence in last decades. About 95% of all TCs are represented by testicular germ cell tumors (TGCTs), which include seminoma and non-seminoma histological types. It is generally assumed that the development of TGCT is under endocrine control. In particular, unbalanced androgen/estrogen levels and/or activity are believed to represent the key events for TGCT development and progression. Furthermore, recent evidence has suggested genetic association of TGCT with variations in genes involved in hypothalamic-pituitary-testicular axis and steroidogenic enzymes. This recent evidence expands the current knowledge on the role of genetic contribution in testicular cancer susceptibility, and supports the hypothesis that variations in hormone metabolism genes might change the hormonal environment implicated in testicular carcinogenesis. Therefore, hormonal carcinogenesis is an important and controversial area of current research in TGCT, and further attention is given to genetic factors influencing hormone-related cancer risk. The genetic component to TGCT is in general strong. In fact, although environmental factors clearly contribute to TGCT development (and probably to its increasing incidence in some geographical areas), the proportion of TGCT susceptibility accounted for by the genetic effects is estimated at 25%. TGCT has high familial risks compared with most other cancer types that are generally no more than two-fold: brothers of individuals with TGCT have an 8- to 12-fold increased risk of disease, and sons of affected individuals have a 4- to 6-fold increased risk. Despite this strong familial relative risk, early results from linkage studies identified a limited relationship with genetic factors, suggesting that TGCT is a genetically complex trait. However, more recently, four genome-wide association studies (GWAS) from the UK and USA have reported association of TGCTs with six new loci (KITLG, SPRY4, BAK1, DMRT1, TERT, and ATF7IP). The strongest association for TGCT susceptibility was found for SNPs in KITLG (ligand for the membrane-bound receptor tyrosine kinase KIT) gene with a greater than 2.5-fold increased risk of disease per major allele, which is the highest reported for any cancer to date. These studies are being now replicated by other researches and attention is given to the relationship between these genetic variations, TGCT risk and frequently associated anomalies of the reproductive tract, such as cryptorchidism and infertility. Finally, over the past few decades, TCGT research has focused also on external environmental causes acting mainly as endocrine disrupters of androgen and oestrogen pathways, even during the foetal development of the testis. It is well known that the testicular dysgenesis syndrome (TDS) hypothesis, proposed ten years ago, suggests that disturbed testicular development in fetal life may result in one or more of four disorders postnatally, named cryptorchidism, hypospadias, poor semen quality, and TGCT. These four disorders are therefore considered as one clinical entity and are linked together by epidemiological and pathophysiological relations. The relative contribution of genetics and environment in TGCT development, and the interactions between endocrine disruptors and variations in genes involved in hormonal carcinogenesis is therefore another interesting area of research.
The field of gender-specific medicine examines how normal human biology and physiology differ between men and women and how the diagnosis and treatment of disease differs as a function of gender. This revealing research covers various conditions that predominantly occur in men as well conditions that predominantly occur in women. Among the areas of greatest difference are cardiovascular disease, mood disorders, the immune system, lung cancer as a consequence of smoking, osteoporosis, diabetes, obesity, and infectious diseases. The Second Edition of Principles of Gender-Specific Medicine focuses on the essentials of gender-specific medicine and the current study of sex and gender differences in human physiology and pathophysiology. New section editors, new chapter authors, and new chapters have been added to reflect the most up-to-date clinical research and practice. - Offers insight into how the gender-specific risks of one organ system's disease affects the health of other organ systems - Outlines the sex-specific differences of normal anatomy and physiology - Illustrates the gender-specific features and quantifies "gender" and "sex" as risk factors across all major diseases - Qualifies and analyzes the results of new drug therapies designed with gender-specific differences in mind: ex, hormone therapy in men and women for the prevention and treatment of cardiovascular disease - All chapters progress translationally from the basic science to the clinical applications of gender-specific therapies, drugs, or treatments - Sections on drug metabolism, aging, and meta-analysis of data incorporated into all disease-specific chapters
Knowledge in the field of urologic pathology is growing at an explosive pace. Today’s pathologists, specialists, and residents require a comprehensive and authoritative text that examines the full range of urological diseases and their diagnosis. Written by recognized leaders and educators in the field, the text provides readers with a detailed understanding of all diagnostic aspects of urological disease. Inside this unique resource, readers will explore a broad spectrum of practical information—including etiology, diagnostic criteria, molecular markers, differential diagnosis, ancillary tests, and clinical management. This is sure to be the new definitive text for urological pathology!
This is the first comprehensive book devoted exclusively to cancer in adolescents and young adults. It compiles medical, epidemiological, biological, psychological, and emotional issues of young adults’ oncology. The emphasis is on the differences of the "same" cancer in younger and older patients. Model programs specially designed to care for patients in the age group and surveillance of long-term adverse effects are reviewed.
Some investigators have hypothesized that estrogens and other hormonally active agents found in the environment might be involved in breast cancer increases and sperm count declines in humans as well as deformities and reproductive problems seen in wildlife. This book looks in detail at the science behind the ominous prospect of "estrogen mimics" threatening health and well-being, from the level of ecosystems and populations to individual people and animals. The committee identifies research needs and offers specific recommendations to decision-makers. This authoritative volume: Critically evaluates the literature on hormonally active agents in the environment and identifies known and suspected toxicologic mechanisms and effects of fish, wildlife, and humans. Examines whether and how exposure to hormonally active agents occursâ€"in diet, in pharmaceuticals, from industrial releases into the environmentâ€"and why the debate centers on estrogens. Identifies significant uncertainties, limitations of knowledge, and weaknesses in the scientific literature. The book presents a wealth of information and investigates a wide range of examples across the spectrum of life that might be related to these agents.
This book provides the reader with a comprehensive understanding of both the basic principles and the clinical applications of nuclear oncology imaging techniques. The authors have assembled a distinguished group of leaders in the field who provide valuable insight on the subject. The book also includes major chapters on the cancer patient and the pathophysiology of abnormal tissue, the evaluation of co-existing disease, and the diagnosis and therapy of specific tumors using functional imaging studies. Each chapter is heavily illustrated to assist the reader in understanding the clinical role of nuclear oncology in cancer disease therapy and management.
Germ cell tumors are relatively rare compared with other malignancies, and compilations of knowledge that encompass the entire spectrum of the disease are lacking. This textbook, written by the foremost authorities in the field, rectifies the situation by discussing in depth a broad range of topics, including biology, epidemiology, pathology, treatment, and late effects. Bearing in mind that germ cell tumors are most prevalent in the adolescent and young adult age group, causes of disease and treatment approaches in pediatric and adult patients are compared and contrasted. By spanning the entire life course, from prenatal origins of disease through to treatment in adults and late effects of treatment, the editors have produced a book that will be of interest to both pediatric and adult oncologists.
This new volume in the WHO series on histological and genetic typing of human tumors covers tumors of the kidney, the urinary system, the prostate, the testis and paratesticular tissue and the penis. Each entity is extensively discussed with information on clinicopathological, epidemiological, immunophenotypic and genetic aspects of these diseases. This book is an authoritative, concise reference, prepared by 131 authors from 22 countries. It contains more than 800 color photographs, numerous MRIs, ultrasound images, CT scans, charts and 3000 references.This book is in the series commonly referred to as the "Blue Book" series."Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs"Contributors:: Dr Lauri A. Aaltonen, Dr Ferran Algaba, Dr William C. Allsbrook Jr., Dr Isabel Alvarado-Cabrero, Dr Mahul B. Amin, Dr Pedram Argani, Dr Hans Arnholdt, Dr Alberto G. Ayala, Dr Sheldon Bastacky, Dr Louis R. Begin, Dr Athanase Billis, Dr Liliane Boccon-Gibod, Dr Stephen M. Bonsib, Dr Christer Busch, Dr Paul Cairns, Dr Liang Cheng, Dr John Cheville, Dr Carlos Cordon-Cardo, Dr Antonio L. Cubilla, Dr Ivan Damjanov, Dr Charles J. Davis, Dr Angelo M. De Marzo, Dr Louis P. Dehner, Dr Brett Delahunt, Dr Gonzague De Pinieux, Dr P. Anthony Di Sant agnese, Dr Joakim Dillner, Dr John N. Eble, Dr Diana M. Eccles, Dr Lars Egevad, Dr M.N. El-Bolkainy, Dr Jonathan I. Epstein, Dr John F. Fetsch, Dr Masakuni Furusato, Dr Thomas Gasser, Dr William L. Gerald, Dr A. Geurts Van Kessel, Dr David J. Grignon, Dr Kenneth Grigor, Dr Jay L. Grosfeld, Dr Louis Guillou Dr Seife Hailemariam, Professor Ulrike Maria Hamper, Dr Arndt Hartmann, Dr Tadashi Hasegawa, Dr Axel Heidenreich, Dr Philipp U. Heitz, Dr Burkhard Helpap, Dr Riitta Herva, Professor Ferdinand Hofstadter, Professor Simon Horenblas, Dr Peter A. Humphrey, Dr Kenneth A. Iczkowski, Dr Grete Krag Jacobsen, Dr Sonny L. Johansson, Dr Michael A. Jones, Dr Peter A. Jones, Dr George W. Kaplan, Dr Charles E. Keen, Dr Kyu Rae Kim, Dr Maija Kiuru, Dr Paul Kleihues, Dr Margaret A. Knowles, Dr Gyula Kovacs, Dr Marc Ladanyi, Dr Virpi Launonen, Dr Ivo Leuschner, Dr Howard S. Levin, Dr W. Marston Linehan, Dr Leendert H.J. Looijenga, Dr Antonio Lopez-Beltran, Dr J. Carlos Manivel, Dr Guido Martignoni, Dr Alexander Marx, Dr David G. Mcleod, Dr L. Jeffrey Medeiros, Dr Maria J. Merino, Dr Helen Michael, Dr Markku Miettinen, Dr Holger Moch, Dr Henrik Moller, Dr Rodolfo Montironi, Dr F. Kash Mostofi, Dr Hartmut P.H. Neumann, Dr Manuel Nistal, Dr Lucien Nochomovitz, Dr Esther Oliva, Dr Tim D. Oliver, Dr J. Wolter Oosterhuis, Dr Attilio Orazi, Dr Chin-Chen Pan, Dr Ricardo Paniagua, Dr David M. Parham, Dr D. Max Parkin, Dr M. Constance Parkinson, Dr Christian P. Pavlovich, Dr Elizabeth J. Perlman, Dr Paola Pisani, Dr Andrew A. Renshaw, Dr Victor E. Reuter, Dr Jae Y. Ro, Professor Mark A. Rubin, Dr H. Gil Rushton, Dr Wael A. Sakr, Dr Hemamali Samaratunga, Dr Guido Sauter, Dr Paul F. Schellhammer, Dr Bernd J. Schmitz-Drager, Dr Mark Philip Schoenberg, Dr Isabell A. Sesterhenn, Dr David Sidransky, Dr Ronald Simon, Dr Leslie H. Sobin, Dr Poul H. B. Sorensen, Dr John R. Srigley, Dr Stephan Storkel, Dr Aleksander Talerman, Dr Pheroze Tamboli, Dr Puay H. Tan, Dr Bernard Tetu, Dr Kaori Togashi, Dr Lawrence True, Dr Jerzy E. Tyczynski, Dr Thomas M. Ulbright, Dr Eva Van Den Berg, Dr Theo H. Van Der Kwast, Dr Annick Vieillefond, Dr Geo Von Krogh, Dr Thomas Wheeler, Dr Paula J. Woodward, Dr Ximing J. Yang, Dr Berton Zbar"
